top of page
Pipeline
Pipeline
Phase 3
Phase 2
Target Validation
IND Studies
Phase 1
Phase 2
Phase 3
Target
Colon Cancer
Si44
Target: Xkr8(Oxp)
SMT1
Breast Cancer
Target: iRhom(Dox)
SMT1
SMT
NHL
Target: NTarget
Si44
NSCLC
SMT
Target: mutEGFR
SMT
We built the Trident platform to enable targeting a wide range of cancers – our pipeline is led by POS001, aimed at NSCLC, and followed by other solid tumor indications as well as ALL.
Si44
Colon Cancer
Breast Cancer
44-FREE
NHL